Optimal cytoreduction in advanced ovarian cancer treated with dose-dense paclitaxel and carboplatin followed by interval surgery at the Peruvian national institute of neoplastic diseases

Descripción del Articulo

Objectives. To determine the rate of optimal cytoreduction in patients with advanced ovarian cancer who received neoadjuvant chemotherapy with dose-dense carboplatin and paclitaxel followed by interval debulking surgery (IDS). Materials and Methods. A retrospective study of a series of cases of Peru...

Descripción completa

Detalles Bibliográficos
Autores: Alcarraz Molina, Cindy, Muñiz, Johana, Mas, Luis, Olivera, Mivael, Morante, Zaida
Formato: artículo
Fecha de Publicación:2018
Institución:Instituto Nacional de Enfermedades Neoplásicas
Repositorio:INEN-Institucional
Lenguaje:español
OAI Identifier:oai:repositorio.inen.sld.pe:20.500.14703/455
Enlace del recurso:https: //doi.org/10.17843/rpmesp.2018.351.3599
https://hdl.handle.net/20.500.14703/455
Nivel de acceso:acceso abierto
Materia:Chemotherapy
Cytoreduction surgical procedures
Neoadjuvant therapy
Ovarian neoplasms
Peru
https://purl.org/pe-repo/ocde/ford#3.02.21
id INEN_de7df0130e1a5b7666d71de08d246947
oai_identifier_str oai:repositorio.inen.sld.pe:20.500.14703/455
network_acronym_str INEN
network_name_str INEN-Institucional
repository_id_str .
dc.title.none.fl_str_mv Optimal cytoreduction in advanced ovarian cancer treated with dose-dense paclitaxel and carboplatin followed by interval surgery at the Peruvian national institute of neoplastic diseases
title Optimal cytoreduction in advanced ovarian cancer treated with dose-dense paclitaxel and carboplatin followed by interval surgery at the Peruvian national institute of neoplastic diseases
spellingShingle Optimal cytoreduction in advanced ovarian cancer treated with dose-dense paclitaxel and carboplatin followed by interval surgery at the Peruvian national institute of neoplastic diseases
Alcarraz Molina, Cindy
Chemotherapy
Cytoreduction surgical procedures
Neoadjuvant therapy
Ovarian neoplasms
Peru
https://purl.org/pe-repo/ocde/ford#3.02.21
title_short Optimal cytoreduction in advanced ovarian cancer treated with dose-dense paclitaxel and carboplatin followed by interval surgery at the Peruvian national institute of neoplastic diseases
title_full Optimal cytoreduction in advanced ovarian cancer treated with dose-dense paclitaxel and carboplatin followed by interval surgery at the Peruvian national institute of neoplastic diseases
title_fullStr Optimal cytoreduction in advanced ovarian cancer treated with dose-dense paclitaxel and carboplatin followed by interval surgery at the Peruvian national institute of neoplastic diseases
title_full_unstemmed Optimal cytoreduction in advanced ovarian cancer treated with dose-dense paclitaxel and carboplatin followed by interval surgery at the Peruvian national institute of neoplastic diseases
title_sort Optimal cytoreduction in advanced ovarian cancer treated with dose-dense paclitaxel and carboplatin followed by interval surgery at the Peruvian national institute of neoplastic diseases
author Alcarraz Molina, Cindy
author_facet Alcarraz Molina, Cindy
Muñiz, Johana
Mas, Luis
Olivera, Mivael
Morante, Zaida
author_role author
author2 Muñiz, Johana
Mas, Luis
Olivera, Mivael
Morante, Zaida
author2_role author
author
author
author
dc.contributor.author.fl_str_mv Alcarraz Molina, Cindy
Muñiz, Johana
Mas, Luis
Olivera, Mivael
Morante, Zaida
dc.subject.none.fl_str_mv Chemotherapy
Cytoreduction surgical procedures
Neoadjuvant therapy
Ovarian neoplasms
Peru
topic Chemotherapy
Cytoreduction surgical procedures
Neoadjuvant therapy
Ovarian neoplasms
Peru
https://purl.org/pe-repo/ocde/ford#3.02.21
dc.subject.ocde.none.fl_str_mv https://purl.org/pe-repo/ocde/ford#3.02.21
description Objectives. To determine the rate of optimal cytoreduction in patients with advanced ovarian cancer who received neoadjuvant chemotherapy with dose-dense carboplatin and paclitaxel followed by interval debulking surgery (IDS). Materials and Methods. A retrospective study of a series of cases of Peruvian women treated with neoadjuvant chemotherapy with carboplatin (6 AUC mg/mL/min) and paclitaxel (80 mg/m2 weekly) followed by IDS, at the National Institute of Neoplastic Diseases during the 2010-2014 period. Results. The 41 patients who made it to the interval surgery had a median age of 59 years (range: 47-73 years). In 37 (90.2%) patients, high-grade serous adenocarcinoma histology was reported. Thirty-four (82.9%) achieved optimal cytoreduction and five (14.7%), a complete pathological response. Progression-free survival at one year and two years was 74.7% and 51.8%, respectively. Overall survival at one year and two years was 85.2% and 71.4%, respectively. The risk of progression and death was greater in patients without optimal cytoreduction and in patients with post-surgery levels of carcinoembryonic antigen 125 > 30 U/mL. Conclusions. Neoadjuvant therapy with dose-dense carboplatin and paclitaxel achieved an elevated frequency of optimal cytoreduction. The post-surgery levels of carcinoembryonic antigen 125 and optimal cytoreduction were independent factors of progression-free survival and overall survival.
publishDate 2018
dc.date.accessioned.none.fl_str_mv 2025-08-21T04:22:42Z
dc.date.available.none.fl_str_mv 2025-08-21T04:22:42Z
dc.date.issued.fl_str_mv 2018
dc.type.none.fl_str_mv info:eu-repo/semantics/article
dc.type.version.none.fl_str_mv info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.doi.none.fl_str_mv https: //doi.org/10.17843/rpmesp.2018.351.3599
dc.identifier.uri.none.fl_str_mv https://hdl.handle.net/20.500.14703/455
dc.identifier.journal.none.fl_str_mv Revista Peruana de Medicina Experimental y Salud Publica
url https: //doi.org/10.17843/rpmesp.2018.351.3599
https://hdl.handle.net/20.500.14703/455
identifier_str_mv Revista Peruana de Medicina Experimental y Salud Publica
dc.language.iso.none.fl_str_mv spa
language spa
dc.rights.none.fl_str_mv info:eu-repo/semantics/openAccess
dc.rights.uri.none.fl_str_mv https://creativecommons.org/licenses/by/4.0/
eu_rights_str_mv openAccess
rights_invalid_str_mv https://creativecommons.org/licenses/by/4.0/
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv Instituto Nacional de Salud
dc.publisher.country.none.fl_str_mv PE
publisher.none.fl_str_mv Instituto Nacional de Salud
dc.source.none.fl_str_mv reponame:INEN-Institucional
instname:Instituto Nacional de Enfermedades Neoplásicas
instacron:INEN
instname_str Instituto Nacional de Enfermedades Neoplásicas
instacron_str INEN
institution INEN
reponame_str INEN-Institucional
collection INEN-Institucional
bitstream.url.fl_str_mv https://repositorio.inen.sld.pe/backend/api/core/bitstreams/ff353ba4-5f19-4e12-9011-3161c3512104/download
https://repositorio.inen.sld.pe/backend/api/core/bitstreams/50eb46b1-6af9-4edd-930a-fe39e33f8dc0/download
https://repositorio.inen.sld.pe/backend/api/core/bitstreams/4758f7c2-d55d-4423-b924-84ca4b0d03db/download
https://repositorio.inen.sld.pe/backend/api/core/bitstreams/e4c6a931-481b-495a-bec7-82ef51d607af/download
bitstream.checksum.fl_str_mv 3dec5977c31c83b9f09bb076b619657b
bb9bdc0b3349e4284e09149f943790b4
01aa4c5f77232e047ccdc2f50272e90e
ffbc23babd54dc31c21a67c417dd7dd5
bitstream.checksumAlgorithm.fl_str_mv MD5
MD5
MD5
MD5
repository.name.fl_str_mv Repositorio del Instituto Nacional de Enfermedades Neoplásicas
repository.mail.fl_str_mv repositorio@inen.sld.pe
_version_ 1868438552258281472
spelling PublicationAlcarraz Molina, CindyMuñiz, JohanaMas, LuisOlivera, MivaelMorante, Zaida2025-08-21T04:22:42Z2025-08-21T04:22:42Z2018https: //doi.org/10.17843/rpmesp.2018.351.3599https://hdl.handle.net/20.500.14703/455Revista Peruana de Medicina Experimental y Salud PublicaObjectives. To determine the rate of optimal cytoreduction in patients with advanced ovarian cancer who received neoadjuvant chemotherapy with dose-dense carboplatin and paclitaxel followed by interval debulking surgery (IDS). Materials and Methods. A retrospective study of a series of cases of Peruvian women treated with neoadjuvant chemotherapy with carboplatin (6 AUC mg/mL/min) and paclitaxel (80 mg/m2 weekly) followed by IDS, at the National Institute of Neoplastic Diseases during the 2010-2014 period. Results. The 41 patients who made it to the interval surgery had a median age of 59 years (range: 47-73 years). In 37 (90.2%) patients, high-grade serous adenocarcinoma histology was reported. Thirty-four (82.9%) achieved optimal cytoreduction and five (14.7%), a complete pathological response. Progression-free survival at one year and two years was 74.7% and 51.8%, respectively. Overall survival at one year and two years was 85.2% and 71.4%, respectively. The risk of progression and death was greater in patients without optimal cytoreduction and in patients with post-surgery levels of carcinoembryonic antigen 125 > 30 U/mL. Conclusions. Neoadjuvant therapy with dose-dense carboplatin and paclitaxel achieved an elevated frequency of optimal cytoreduction. The post-surgery levels of carcinoembryonic antigen 125 and optimal cytoreduction were independent factors of progression-free survival and overall survival.application/pdfspaInstituto Nacional de SaludPEinfo:eu-repo/semantics/openAccesshttps://creativecommons.org/licenses/by/4.0/ChemotherapyCytoreduction surgical proceduresNeoadjuvant therapyOvarian neoplasmsPeruhttps://purl.org/pe-repo/ocde/ford#3.02.21Optimal cytoreduction in advanced ovarian cancer treated with dose-dense paclitaxel and carboplatin followed by interval surgery at the Peruvian national institute of neoplastic diseasesinfo:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionreponame:INEN-Institucionalinstname:Instituto Nacional de Enfermedades Neoplásicasinstacron:INENORIGINALadminojs,+8.pdfadminojs,+8.pdfapplication/pdf298906https://repositorio.inen.sld.pe/backend/api/core/bitstreams/ff353ba4-5f19-4e12-9011-3161c3512104/download3dec5977c31c83b9f09bb076b619657bMD51trueAnonymousREADLICENSElicense.txtWritten by org.dspace.content.LicenseUtilstext/plain; charset=utf-81748https://repositorio.inen.sld.pe/backend/api/core/bitstreams/50eb46b1-6af9-4edd-930a-fe39e33f8dc0/downloadbb9bdc0b3349e4284e09149f943790b4MD52falseAnonymousREADTEXTadminojs,+8.pdf.txtWritten by FormatFilter org.dspace.app.mediafilter.TikaTextExtractionFilter on 2025-08-21T08:02:42Z (GMT).Extracted texttext/plain40539https://repositorio.inen.sld.pe/backend/api/core/bitstreams/4758f7c2-d55d-4423-b924-84ca4b0d03db/download01aa4c5f77232e047ccdc2f50272e90eMD53falseAnonymousREADTHUMBNAILadminojs,+8.pdf.jpgWritten by FormatFilter org.dspace.app.mediafilter.PDFBoxThumbnail on 2025-08-21T08:02:43Z (GMT).Generated Thumbnailimage/jpeg44520https://repositorio.inen.sld.pe/backend/api/core/bitstreams/e4c6a931-481b-495a-bec7-82ef51d607af/downloadffbc23babd54dc31c21a67c417dd7dd5MD54falseAnonymousREAD20.500.14703/455oai:repositorio.inen.sld.pe:20.500.14703/4552026-02-17T14:12:01.248Zhttps://creativecommons.org/licenses/by/4.0/info:eu-repo/semantics/openAccessopen.accesshttps://repositorio.inen.sld.peRepositorio del Instituto Nacional de Enfermedades Neoplásicasrepositorio@inen.sld.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
score 12.824051
Nota importante:
La información contenida en este registro es de entera responsabilidad de la institución que gestiona el repositorio institucional donde esta contenido este documento o set de datos. El CONCYTEC no se hace responsable por los contenidos (publicaciones y/o datos) accesibles a través del Repositorio Nacional Digital de Ciencia, Tecnología e Innovación de Acceso Abierto (ALICIA).